poliovirus vaccines


Also found in: Dictionary, Thesaurus.
Related to poliovirus vaccines: poliomyelitis vaccine

po·li·o·vi·rus vac·cines

1. inactivated poliovirus vaccine (IPV), an aqueous suspension of inactivated strains of poliomyelitis virus (types 1, 2, and 3) used by injection; has largely been replaced by the oral vaccine;
2. oral poliovirus vaccine (OPV), an aqueous suspension of live, attenuated strains of poliomyelitis virus (types 1, 2, and 3) given orally for active immunization against poliomyelitis.
References in periodicals archive ?
Endemic poliomyelitis has been eliminated from most parts of the world by vaccination with live attenuated oral poliovirus vaccine (OPV) and inactivated poliovirus vaccine (IPV) (3).
Shedding of vaccine viruses with increased antigenic and genetic divergence after vaccination of newborns with monovalent type 1 oral poliovirus vaccine.
Global Introduction of Inactivated Poliovirus Vaccine
As a result, the type 2 component of oral poliovirus vaccine is slated for global withdrawal through a switch from trivalent oral poliovirus vaccine (tOPV) to bivalent oral poliovirus vaccine (bOPV).
The ACIP, an advisory group of the Centers for Disease Control and Prevention, recommended a sequential schedule of 2 doses of inactivated poliovirus vaccine (IPV) followed by 2 doses of oral poliovirus vaccine (OPV), but also considered the all OPV or IPV schedules acceptable.
Antibody titers increased at least 30-fold after administration of the poliovirus vaccine booster dose at age 18 months.
IPV is the only poliovirus vaccine recommended for immunocompromised persons and their household contacts.
A resurgence in wild poliovirus (WPV) transmission occurred in Nigeria during 2003-2004 after a loss of public confidence in oral poliovirus vaccine (OPV) and suspension of supplementary immunization activities (SIAs) * in several northern states (1).
The cost of Pediarix is currently 4%-5% above the combined cost of DTaP, hepatitis B (recombinant), and inactivated poliovirus vaccines, said Dr.
In January 1997, the Food and Drug Administration (FDA) approved an amendment to the package labeling for the inactivated poliovirus vaccine (IPV) currently licensed in the United States, allowing the third dose of this IPV in an all-IPV schedule to be administered as early as age 6 months.
In addition, poliovirus vaccine has been offered to members of all unvaccinated communities.
First, it called on all countries to introduce at least one dose of inactivated poliovirus vaccine by the third quarter of 2015, immunizing infants at 14 weeks or at first contact thereafter.